1. J. M. Young, P. J. Maloney, S. N. Jubb and J. S. Clark,Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse. Prostaglandins30, 545–551 (1985).
2. T. Yamada, K. Tomioka, M. Saito, M. Horie, T. Mase, H. Hara and H. Nagaoka,Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor. Arch. Int. Pharmacodyn. Ther.308, 123–136 (1990).
3. H. Tsunoda, Y. Sakuma, K. Harada, K. Muramoto, S. Katayama, T. Horie, N. Shimomura, R. Clark, S. Miyazawa, K. Okano, Y. Machida, K. Katayama and I. Yamatsu,Pharmacological activities of novel thienodiazepine derivative as a platelet-activating factor antagonist. Arzneim.-forsch./Drug Res.40, 1201–1205 (1990).
4. J. M. Herbet, A. Bernat, G. Valette, V. Gigo, A. Lale, M. C. Laplace, L. Lespy, P. Savi, J. P. Maffrand and G. Le Fur,Biochemical and pharmacological activities of SR27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J. Pharmacol. Exp. Ther.259, 44–51 (1991).
5. D. E. Guinn, J. B. Summers, H. R. Heyman, R. G. Conway, D. A. Rhein, D. H. Albert, T. Magoc and G. W. Carter,Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet-activating factor antagonists. J. Med. Chem.35, 2055–2061 (1992).